(VRDN) – FDA
-
Viridian Therapeutics (VRDN) to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
-
Viridian Therapeutics (VRDN) Reports Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program
-
-
-
-
-
-
-
-
Back to VRDN Stock Lookup